Candriam S.C.A. Medpace Holdings, Inc. Transaction History

Candriam S.C.A.

$16.8 Billion
Q2 2025

A detailed history of Candriam S.C.A. transactions in Medpace Holdings, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 51,655 shares of MEDP stock, worth $28.1 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

51,655

Previous 60,317 14.36%

Holding current value

$28.1 Million

Previous $18.4 Million 11.78%

% of portfolio

0.1%

Previous 0.12%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$277.23 - $315.28 $2.4 Million - $2.73 Million	-8,662 Reduced 14.36%	51,655 $16.2 Million
Q1 2025 May 14, 2025	SELL	$304.69 - $360.97 $266,603 - $315,848	-875 Reduced 1.43%	60,317 $18.4 Million
Q4 2024 Feb 06, 2025	SELL	$308.93 - $363.58 $6.82 Million - $8.03 Million	-22,089 Reduced 26.52%	61,192 $20.3 Million
Q3 2024 Nov 13, 2024	BUY	$320.58 - $457.29 $2.8 Million - $3.99 Million	8,720 Added 11.7%	83,281 $27.8 Million
Q2 2024 Aug 05, 2024	BUY	$372.0 - $424.34 $20.2 Million - $23 Million	54,255 Added 267.19%	74,561 $30.7 Million
Q1 2024 May 03, 2024	BUY	$284.87 - $413.31 $5.78 Million - $8.39 Million	20,306 New	20,306 $8.21 Million
Q3 2023 Nov 13, 2023	SELL	$233.98 - $281.67 $969,613 - $1.17 Million	-4,144 Reduced 41.88%	5,750 $1.39 Million
Q2 2023 Aug 08, 2023	BUY	$187.26 - $240.17 $1.15 Million - $1.48 Million	6,157 Added 164.76%	9,894 $2.38 Million
Q1 2023 May 12, 2023	BUY	$174.31 - $239.52 $651,396 - $895,086	3,737 New	3,737 $702,000
Q3 2022 Nov 10, 2022	BUY	$145.13 - $182.49 $3.15 Million - $3.97 Million	21,729 New	21,729 $3.42 Million

Others Institutions Holding MEDP

# of Institutions

676

Shares Held

27M

Call Options Held

53.6K

Put Options Held

108K

View Full List

About Medpace Holdings, Inc.

Ticker MEDP
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 31,099,900
Market Cap $16.9B
Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, bi...

More about MEDP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account